Yerevan
Tbilisi
Moscow
Paris
Los Angeles
Beijing
English
Հայերեն Русский
Main Timeline Video Share
May the Holiday Warm Hearts: Idram and IDBank Support the Children of Heroes Beneficiaries of the "By Your Side" program at IDBank AraratBank Named Large CSR Company of the Year Idram Joins the Fight Against Food Insecurity Ucom’s Renovated Sales and Service Center in Yerevan Mall Reopens 1% idcoin instead of New Year’s suffering: practical tips Idram Junior Donated Books to Schools Big Christmas Market with Idram, IDBank and idplus Ucom Supports Wildlife Monitoring in Ararat Region IDBank, Idram, and idplus at the Big Christmas Market Converse Bank Deputy CEO and CFO, Grant Akopian, Elected to BACEE Board Ucom and SunChild NGO Install a Solar Plant in Alaverdi Kindergarten
Timeline
The Power of One Dram Joins the Final Phase of the Symphonic Forest ProjectIdram&IDBank’s Special Offer at Dalma Garden MallUcom’s Management Team Marks International Client’s Day with Subscribers IDBank and Idram Continue Cooperation with the “ZARK” Educational FoundationIDBank issued the 2nd and 3rd tranches of bonds of 2026Ucom Issues Warning on New Wave of Phone Scams IDBank Launches Special Campaign for SWIFT TransfersConverse Bank shares its capital market expertise at the IV Conference Capital Markets ArmeniaUcom’s Level Up+ Packages with the Fastest Mobile Internet in Armenia The Badalyan Brothers Group of Companies Paid about 33.2 Billion AMD in Taxes and Duties to the State in 2025IDBank Announces the Launch of the IDDistributor Financial ToolSafe Workplace as a Guarantee of DevelopmentSpring Promotion at Megamall from Idram&IDBank“We want to buy your item, please provide your card details.” IDBank warns about fraud on classified platforms Ucom Fellowship 2025 Concludes as Top Eco-Startups Secure FundingIDBank Goes International: Mher Abrahamyan's Interview with the Los Angeles TimesAraratBank Earns RIA Money Transfer’s Partner of the Year in Armenia for the Seventh Consecutive YearUcom Supports the “DemArDem 2026” Regional Youth Forum ZCMC еstablishes Sustainability, ESG and Risk Committee Parallels Between the “Real Armenia Ideology” and Soviet and Turkish Approaches to the Diaspora
All Timeline »
Life

Multiple sclerosis drug shows promising efficacy

The multiple sclerosis drug is showing promising efficacy in fighting relapses and reducing fatigue.

Back in March 2001, the US Food and Drug Administration approved a drug called ponosimod for use in adult patients with various types of multiple sclerosis. Only now there are research data that show that some drug reduces the number of relapses of the disease and can reduce fatigue - one of the characteristic symptoms of multiple sclerosis.

The respected scientific journal JAMA Neurology has found that ponesimod is more effective in fighting fatigue in multiple sclerosis than another commonly used drug called teriflunomide. It is superior to teriflunomide in reducing relapse rates and reducing the risk of new or existing lesions of myelin found on magnetic resonance imaging.

As reported by everydayhealth.com, ponesimod is used for various types of multiple sclerosis, including the most common relapsing remitting disease and active secondary progressive, which is the most severe. It is not accompanied by remissions and steadily leads to the disability of patients. It is people with this form of multiple sclerosis who show the appearance of new lesions of the myelin layer on MRI scans. Ponesimod must be taken once a day, treatment begins with a period of 14 days, then the doses are increased.